<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065869</url>
  </required_header>
  <id_info>
    <org_study_id>BP-004</org_study_id>
    <nct_id>NCT02065869</nct_id>
  </id_info>
  <brief_title>Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant</brief_title>
  <official_title>Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate pediatric patients with malignant or non-malignant blood cell&#xD;
      disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa&#xD;
      and beta cells that comes from a partially matched family donor. The study will assess&#xD;
      whether immune cells, called T cells, from the family donor, that are specially grown in the&#xD;
      laboratory and given back to the patient along with the stem cell transplant can help the&#xD;
      immune system recover faster after transplant. As a safety measure these T cells have been&#xD;
      programmed with a self-destruct switch so that they can be destroyed if they start to react&#xD;
      against tissues (Graft versus host disease).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II extension study evaluating the safety and feasibility of BPX-501 T cells&#xD;
      infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic&#xD;
      stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to&#xD;
      determine whether BPX-501 infusion can enhance immune reconstitution in those patients with&#xD;
      hematologic disorders, with the potential for reducing the severity and duration severe acute&#xD;
      graft versus host disease (GvHD).&#xD;
&#xD;
      The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug&#xD;
      (AP1903/rimiducid) in those subjects who present with GVHD who progress or do not respond to&#xD;
      standard of care treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">February 2033</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free -Survival</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>events include TRM (or NRM for malignant patients), severe GVHD (acute Grade 2-4 organ or extensive chronic GVHD) and life threatening infections (Grade 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRM (non-malignant) or NRM (malignant)</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>transplant related mortality or non relapse mortality (patients with malignant disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence and severity of acute (grade 2-4) and chronic GvHD at 180 days</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>grades 2-4 acute and chronic GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of acute GvHD after administration of rimiducid</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>resolution of acute GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>absolute CD3, CD4 and CD8 count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free/cGvHD</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>Disease free/cGvHD survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>Disease status of each specific disease indication</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Leukemia, Acute Myeloid (AML), Child</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Primary Immunodeficiency</condition>
  <condition>Anemia, Aplastic</condition>
  <condition>Osteopetrosis</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Cytopenia</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Diamond Blackfan Anemia</condition>
  <condition>Thalassemia</condition>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).&#xD;
Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BPX-501 T cells</intervention_name>
    <description>1x10E6 cells/kg infused on Day 0</description>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <other_name>rivogenlecleucel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimiducid</intervention_name>
    <description>0.4mg/kg administered IV to treat GVHD</description>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years and &gt; 1 month (&lt; 1 month upon approval by Sponsor)&#xD;
&#xD;
          -  Life expectancy &gt; 10 weeks&#xD;
&#xD;
          -  Patients deemed clinically eligible for allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Patients may have failed prior allograft&#xD;
&#xD;
          -  Patients with life-threatening acute leukemia (high-risk ALL in 1st CR, ALL in 2nd CR,&#xD;
             high-risk AML in 1st CR, AML in 2nd CR.) or myelodysplastic syndromes. Morphological&#xD;
             CR must be documented and minimal residual disease measurement before transplantation&#xD;
             is recommended.&#xD;
&#xD;
          -  Non-malignant disorders deemed curable by allogeneic transplantation: a. primary&#xD;
             immune deficiencies, b. severe aplastic anemia not responding to immune suppressive&#xD;
             therapy, c. osteopetrosis d. selected cases of erythroid disorders such as β0 β0&#xD;
             thalassemia major, sickle cell disease, Diamond-Blackfan anemia.&#xD;
&#xD;
             e. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal&#xD;
             malignant evolution (MDS, AML).&#xD;
&#xD;
        Note: Subjects will be eligible if they meet either item 5 OR item 6.&#xD;
&#xD;
          -  Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically&#xD;
             identical relative or 10/10 unrelated donor evaluated using high resolution molecular&#xD;
             typing) or presence of rapidly progressive disease not permitting time to identify an&#xD;
             unrelated donor&#xD;
&#xD;
          -  A minimum genotypic identical match of 5/10 is required.&#xD;
&#xD;
          -  The donor and recipient must be identical, as determined by high resolution typing, on&#xD;
             at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-&#xD;
             DRB1 and HLA-DQB1.&#xD;
&#xD;
          -  Lansky/Karnofsky score &gt; 50&#xD;
&#xD;
          -  Signed informed consent by the patient or the patient's parent or guardian for&#xD;
             patients who are minors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Greater than active Grade II acute GvHD or chronic extensive GvHD due to a previous&#xD;
             allograft at the time of screening&#xD;
&#xD;
          -  Patient receiving an immunosuppressive treatment for GvHD treatment due to a previous&#xD;
             allograft at the time of screening&#xD;
&#xD;
          -  Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal&#xD;
             value), or of renal function (creatinine clearance &lt;30ml/min/1.73m2)&#xD;
&#xD;
          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or left ventricular ejection fraction &lt; 40%)&#xD;
&#xD;
          -  Current clinically active infectious disease (including positive HIV serology or viral&#xD;
             RNA)&#xD;
&#xD;
          -  Serious concurrent uncontrolled medical disorder&#xD;
&#xD;
          -  Pregnant or breast feeding female patient&#xD;
&#xD;
          -  Lack of parents'/guardian's informed consent for children who are minors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health &amp; Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great North Children's Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <disposition_first_submitted>November 11, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 17, 2020</disposition_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>hematologic neoplasms</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>primary immune deficiences</keyword>
  <keyword>hemoglobinopathy</keyword>
  <keyword>congenital cytopenia</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

